Bayer's Farm Unit Faces a High Bar as Courtroom Testimony and a $2.2 Billion Ohio Bet Converge
Published on 10/09/2026 at 11:20 | Editorial boerse-global.de
A toxicologist took the stand in a Missouri courtroom on Tuesday, telling jurors that a 2017 review by the U.S. Environmental Protection Agency, after weighing the available evidence, found no link between glyphosate and cancer in humans. The testimony came in a case brought by three plaintiffs alleging defective product design tied to the weedkiller Roundup.
That legal front is unfolding alongside a pair of storylines that matter just as much to Bayer's equity story: the durability of its agriculture business and the pace of its pharmaceutical build-out.
JPMorgan Cuts Through the Early Optimism
Richard Vosser, an analyst at JPMorgan, kept his "Overweight" rating on the stock with a price target of 61 euros, but cautioned that the market's early expectations for the third quarter look too rich. His reasoning centers on timing effects in the agricultural division, where demand shifts have long dictated how individual quarters play out.
Traders have little choice but to keep the crop-science unit in their crosshairs ahead of the next reporting milestone, set for November 3. Shares finished the session up 0.5% at EUR 43.15.
A Fresh Multi-Month Low on a Bruised Trading Day
The picture looked considerably darker on a separate, more recent session. Bayer's stock shed 2.1% to EUR 42.95 on Thursday, dragged down by a broadly weak German equity market and landing at its lowest level in several months.
Should investors sell immediately? Or is it worth buying Bayer?
Macro forces did the heavy lifting, according to media accounts: rising bond yields, firmer oil prices and political unease surrounding France all pushed blue chips into the sell column. Even after that retreat, the shares retain a gain of roughly 16% since the start of the year — a reminder that the recent pullback sits atop a still-solid annual advance.
Investors now face a judgment call: whether the latest bout of selling amounts to a market-driven overshoot, or whether fundamental obstacles are about to put an end to the run.
Ohio Manufacturing and a Kidney-Drug Filing
Bayer is pressing ahead with its pharmaceutical expansion regardless of the share-price noise. On October 2, the company unveiled a $2.2 billion investment in a new production site in New Albany, Ohio, expected to generate about 600 permanent positions.
The timeline stretches well into the next decade. Active ingredient output is slated to begin in 2031, with finished-drug manufacturing following in 2034 — a move that widens the group's U.S. production footprint.
Regulatory news arrived from the same corner of the business. The U.S. Food and Drug Administration accepted Bayer's supplemental application for finerenone, marketed as Kerendia, for review. The filing targets adults with chronic kidney disease who do not have diabetes and rests on data from the Phase III FIND-CKD trial. Acceptance marks the start of the formal review process and does not constitute approval of the additional indication.
Elsewhere in the pipeline, Lynkuet received a priority review designation from the FDA for treating vasomotor symptoms in breast cancer patients undergoing endocrine therapy. The cell-therapy candidate lemiretprocel, developed by subsidiary BlueRock Therapeutics, was granted Orphan Drug status in both the U.S. and Europe. Chief Medical Officer Dr. Christoph Koenen's recent appointment rounds out a period of personnel and pipeline activity that could, over the medium term, prompt a broader reassessment of the pharma division.
Bayer at a turning point? This analysis reveals what investors need to know now.
The Balance Sheet Meets a Stubborn Rate Environment
Set against those gains is a risk profile shaped by financial structure and a rate backdrop that shows little sign of easing. Persistently high borrowing costs land hardest on capital-intensive businesses. Bayer did place roughly EUR 2 billion in hybrid bonds about two weeks ago, with maturities of six and nine years, yet refinancing expenses remain a lasting factor in how the stock is valued.
Should upcoming quarterly figures confirm a sustained earnings slump in agriculture, the downward drift could entrench itself. Disappointing margins combined with macroeconomic pressure might prompt institutional investors to trim exposure further — a scenario in which even encouraging drug approvals would be overshadowed by worries about the core divisions.
November 3 as the Decisive Marker
Holding the recent trading range is what matters most for the near term. As long as the stock can stay above its 52-week low and absorb broad market shocks, a stabilization remains within reach. A decisive break below recent interim lows, by contrast, would open the door to further declines.
The next unambiguous turning point is the earnings release on November 3. A farm business that proves more resilient than feared would clear a path back toward the year's highs. If the warnings about muted earnings are borne out, the shares face an extended stretch of weakness — until the new pharma hopefuls can show their full contribution in the numbers.
Ad
Bayer Stock: New Analysis - 9 October
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
